Today’s Stock Alert: A Reversal for Oncomed Pharmaceuticals Inc Is Not Near. The Stock Rises Again

Today's Stock Alert: A Reversal for Oncomed Pharmaceuticals Inc Is Not Near. The Stock Rises Again

The stock of Oncomed Pharmaceuticals Inc (NASDAQ:OMED) is a huge mover today! The stock increased 4.54% or $0.42 on November 23, hitting $9.67. About 118,300 shares traded hands. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) has declined 24.69% since April 22, 2016 and is downtrending. It has underperformed by 30.10% the S&P500.
The move comes after 9 months positive chart setup for the $347.78M company. It was reported on Nov, 24 by Barchart.com. We have $10.25 PT which if reached, will make NASDAQ:OMED worth $20.87 million more.

Analysts await Oncomed Pharmaceuticals Inc (NASDAQ:OMED) to report earnings on March, 9. They expect $-0.68 EPS, down 148.92% or $2.07 from last year’s $1.39 per share. After $-0.77 actual EPS reported by Oncomed Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -11.69% EPS growth.

Oncomed Pharmaceuticals Inc (NASDAQ:OMED) Ratings Coverage

Out of 8 analysts covering OncoMed Pharmaceuticals (NASDAQ:OMED), 7 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 88% are positive. OncoMed Pharmaceuticals has been the topic of 11 analyst reports since September 9, 2015 according to StockzIntelligence Inc. Jefferies maintained the stock with “Buy” rating in Wednesday, August 10 report. Wells Fargo initiated the stock with “Outperform” rating in Friday, December 4 report. The stock of Oncomed Pharmaceuticals Inc (NASDAQ:OMED) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9. Leerink Swann downgraded Oncomed Pharmaceuticals Inc (NASDAQ:OMED) on Monday, January 25 to “Mkt Perform” rating. Mizuho maintained Oncomed Pharmaceuticals Inc (NASDAQ:OMED) rating on Tuesday, January 26. Mizuho has “Buy” rating and $15 price target. As per Wednesday, January 6, the company rating was maintained by Mizuho. Jefferies initiated the shares of OMED in a report on Wednesday, September 9 with “Buy” rating. The firm earned “Buy” rating on Monday, April 18 by Cantor Fitzgerald. The stock of Oncomed Pharmaceuticals Inc (NASDAQ:OMED) has “Buy” rating given on Thursday, September 22 by H.C. Wainwright. BMO Capital Markets initiated it with “Outperform” rating and $20 target price in Tuesday, April 12 report.

According to Zacks Investment Research, “OncoMed Pharmaceuticals, Inc. is a biopharmaceutical company which focuses on the discovering and developing monoclonal antibody therapeutics for cancer stem cells. It utilizes its technologies to identify, isolate and evaluate CSCs, validate multiple potential targets and pathways critical to CSC self-renewal and differentiation and develop antibody and other protein-based therapeutics. The company serves the healthcare industry and cancer therapy patients. OncoMed Pharmaceuticals, Inc. is based in Redwood City, United States.”

Insitutional Activity: The institutional sentiment increased to 2.19 in 2016 Q2. Its up 0.56, from 1.63 in 2016Q1. The ratio increased, as 10 funds sold all Oncomed Pharmaceuticals Inc shares owned while 14 reduced positions. 9 funds bought stakes while 30 increased positions. They now own 9.23 million shares or 8.05% more from 8.54 million shares in 2016Q1.
Tiaa Cref Mngmt Ltd holds 0% of its portfolio in Oncomed Pharmaceuticals Inc (NASDAQ:OMED) for 55,897 shares. Schwab Charles Inv owns 42,821 shares or 0% of their US portfolio. Prtnrs Limited Company holds 0.02% of its portfolio in Oncomed Pharmaceuticals Inc (NASDAQ:OMED) for 24,500 shares. Citigroup Incorporated accumulated 3,594 shares or 0% of the stock. Bank & Trust Of America Corp De has 0% invested in the company for 135,804 shares. Blackrock Management Limited Liability Corporation holds 62,957 shares or 0% of its portfolio. State Street Corporation accumulated 264,839 shares or 0% of the stock. Goldman Sachs Gp reported 27,092 shares or 0% of all its holdings. Qs Limited Com reported 64,307 shares or 0.01% of all its holdings. Creative Planning, a Kansas-based fund reported 300 shares. Alliancebernstein L P accumulated 16,900 shares or 0% of the stock. The Ontario – Canada-based Manufacturers Life The has invested 0% in Oncomed Pharmaceuticals Inc (NASDAQ:OMED). The Vermont-based Birchview L P has invested 0.63% in Oncomed Pharmaceuticals Inc (NASDAQ:OMED). Royal Bank Of Canada holds 0% or 1,200 shares in its portfolio. The New York-based First Eagle Inv Mgmt has invested 0% in Oncomed Pharmaceuticals Inc (NASDAQ:OMED).

Insider Transactions: Since November 16, 2016, the stock had 0 insider purchases, and 1 insider sale for $123,609 net activity. $123,609 worth of Oncomed Pharmaceuticals Inc (NASDAQ:OMED) was sold by Hoey Timothy.

More recent Oncomed Pharmaceuticals Inc (NASDAQ:OMED) news were published by: Fool.com which released: “Why Oncomed Pharmaceuticals Inc’s Share Price (but Not Its Valuation …” on August 18, 2016. Also Marketwatch.com published the news titled: “/quotes/zigman/3870025/realtime” on July 27, 2013. Fool.com‘s news article titled: “Why OncoMed Pharmaceuticals’ Stock Crashed Today” with publication date: January 25, 2016 was also an interesting one.

OMED Company Profile

OncoMed Pharmaceuticals, Inc. (OncoMed), incorporated on July 19, 2004, is a clinical development-stage biopharmaceutical company. The Firm focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company’s product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Anti-DLL4/VEGF Bispecific (OMP-305B83), Anti-RSPO3 (OMP-131R10) and GITRL-Fc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment